Sökning: "PRRT"
Visar resultat 6 - 10 av 16 avhandlingar innehållade ordet PRRT.
6. Therapy with 177Lu-octreotate - pharmacokinetics, dosimetry and kidney toxicity
Sammanfattning : 177Lu-octreotate is used for treatment of patients with somatostatin receptor expressing neuroendocrine tumors in some clinics using a standard schedule. Renal and bone marrow toxicity are the main limiting factors. LÄS MER
7. Strategies for optimisation of 177Lu-octreotate therapy – exploring local administration and combination therapy regimens
Sammanfattning : Neuroendocrine tumours (NETs) are a group of heterogeneous tumour types that originate in hormone-producing organs. Patients with NETs are often diagnosed after the primary tumour has metastasised. LÄS MER
8. Biomarker discovery and assessment for prediction of kidney response after 177Lu-octreotate therapy
Sammanfattning : Patients suffering from neuroendocrine tumors are oftentimes presented with spread disease at the time of diagnosis. Therapy using somatostatin analogs is today the only potentially curative treatment option for these patients. LÄS MER
9. Lutetium-177-octreotate treatment of small intestine neuroendocrine tumors - Radiation biology as basis for optimization
Sammanfattning : Patients with neuroendocrine tumors (NETs) often have metastatic spread at the time of diagnosis. NETs frequently express somatostatin receptors (SSTR) that can be targeted by radiolabeled somatostatin analogs (e.g. 177Lu-octreotate). LÄS MER
10. Tailoring Radionuclide Therapy of Neuroendocrine Tumors - Bridging the Gaps
Sammanfattning : Background and Aims: Radionuclide therapy is systemic, targeted radiotherapy. As such, we can apply the basic principles of radiobiology used in everyday practice in radiation oncology, as a means of tailoring the treatment to each patient and optimizing the balance between efficacy and toxicity. LÄS MER
